NERV vs. VBIV, NRBO, COCP, HUGE, AYTU, ORGS, VAXX, TLPH, AVTX, and VINC
Should you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include VBI Vaccines (VBIV), NeuroBo Pharmaceuticals (NRBO), Cocrystal Pharma (COCP), FSD Pharma (HUGE), Aytu BioPharma (AYTU), Orgenesis (ORGS), Vaxxinity (VAXX), Talphera (TLPH), Avalo Therapeutics (AVTX), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical preparations" industry.
VBI Vaccines (NASDAQ:VBIV) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment.
Minerva Neurosciences has lower revenue, but higher earnings than VBI Vaccines. Minerva Neurosciences is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.
In the previous week, Minerva Neurosciences had 9 more articles in the media than VBI Vaccines. MarketBeat recorded 11 mentions for Minerva Neurosciences and 2 mentions for VBI Vaccines. Minerva Neurosciences' average media sentiment score of 0.55 beat VBI Vaccines' score of 0.47 indicating that VBI Vaccines is being referred to more favorably in the media.
Minerva Neurosciences has a net margin of 0.00% compared to Minerva Neurosciences' net margin of -1,069.29%. VBI Vaccines' return on equity of 0.00% beat Minerva Neurosciences' return on equity.
VBI Vaccines received 153 more outperform votes than Minerva Neurosciences when rated by MarketBeat users. Likewise, 74.74% of users gave VBI Vaccines an outperform vote while only 60.77% of users gave Minerva Neurosciences an outperform vote.
VBI Vaccines has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.
Minerva Neurosciences has a consensus target price of $7.00, suggesting a potential upside of 195.36%. Given VBI Vaccines' higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than VBI Vaccines.
12.3% of VBI Vaccines shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 10.4% of VBI Vaccines shares are owned by company insiders. Comparatively, 6.4% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
VBI Vaccines beats Minerva Neurosciences on 8 of the 15 factors compared between the two stocks.
Get Minerva Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Minerva Neurosciences Competitors List
Related Companies and Tools
